• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

作为拟肽骨架的杂环化合物:固相合成策略

Heterocycles as a Peptidomimetic Scaffold: Solid-Phase Synthesis Strategies.

作者信息

Abdildinova Aizhan, Kurth Mark J, Gong Young-Dae

机构信息

Innovative Drug Library Research Center, Department of Chemistry, College of Science, Dongguk University, 26, 3-ga, Pil-dong, Jung-gu, Seoul 04620, Korea.

Department of Chemistry, University of California, Davis, CA 95616, USA.

出版信息

Pharmaceuticals (Basel). 2021 May 10;14(5):449. doi: 10.3390/ph14050449.

DOI:10.3390/ph14050449
PMID:34068671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8151782/
Abstract

Peptidomimetics are a privileged class of pharmacophores that exhibit improved physicochemical and biological properties. Solid-phase synthesis is a powerful tool for gaining rapid access to libraries of molecules from small molecules to biopolymers and also is widely used for the synthesis of peptidomimetics. Small molecules including heterocycles serve as a core for hundreds of drugs, including peptidomimetic molecules. This review covers solid-phase synthesis strategies for peptidomimetics molecules based on heterocycles.

摘要

肽模拟物是一类具有特殊优势的药效基团,具有改善的物理化学和生物学性质。固相合成是一种强大的工具,可用于快速构建从小分子到生物聚合物的分子库,也广泛用于肽模拟物的合成。包括杂环化合物在内的小分子作为数百种药物(包括肽模拟物分子)的核心。本综述涵盖了基于杂环的肽模拟物分子的固相合成策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/0d6e87fd7450/pharmaceuticals-14-00449-sch015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/73fe2c603e46/pharmaceuticals-14-00449-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/72775595298e/pharmaceuticals-14-00449-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/ef6ea87008a0/pharmaceuticals-14-00449-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/90e57eccdbd4/pharmaceuticals-14-00449-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/55b0c7b88f82/pharmaceuticals-14-00449-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/d1d4f4363166/pharmaceuticals-14-00449-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/2d5c9b463f8c/pharmaceuticals-14-00449-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/0475145a6bdf/pharmaceuticals-14-00449-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/50bea4c5ed15/pharmaceuticals-14-00449-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/3aef6377c7b8/pharmaceuticals-14-00449-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/2faa08ec9b1f/pharmaceuticals-14-00449-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/b34083c2b0e7/pharmaceuticals-14-00449-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/a3270aad15f3/pharmaceuticals-14-00449-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/8d24af825d9a/pharmaceuticals-14-00449-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/561c5956d8a6/pharmaceuticals-14-00449-sch013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/15261c966d55/pharmaceuticals-14-00449-sch014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/0d6e87fd7450/pharmaceuticals-14-00449-sch015.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/73fe2c603e46/pharmaceuticals-14-00449-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/72775595298e/pharmaceuticals-14-00449-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/ef6ea87008a0/pharmaceuticals-14-00449-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/90e57eccdbd4/pharmaceuticals-14-00449-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/55b0c7b88f82/pharmaceuticals-14-00449-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/d1d4f4363166/pharmaceuticals-14-00449-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/2d5c9b463f8c/pharmaceuticals-14-00449-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/0475145a6bdf/pharmaceuticals-14-00449-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/50bea4c5ed15/pharmaceuticals-14-00449-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/3aef6377c7b8/pharmaceuticals-14-00449-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/2faa08ec9b1f/pharmaceuticals-14-00449-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/b34083c2b0e7/pharmaceuticals-14-00449-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/a3270aad15f3/pharmaceuticals-14-00449-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/8d24af825d9a/pharmaceuticals-14-00449-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/561c5956d8a6/pharmaceuticals-14-00449-sch013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/15261c966d55/pharmaceuticals-14-00449-sch014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/702b/8151782/0d6e87fd7450/pharmaceuticals-14-00449-sch015.jpg

相似文献

1
Heterocycles as a Peptidomimetic Scaffold: Solid-Phase Synthesis Strategies.作为拟肽骨架的杂环化合物:固相合成策略
Pharmaceuticals (Basel). 2021 May 10;14(5):449. doi: 10.3390/ph14050449.
2
Recent Reports of Solid-Phase Cyclohexapeptide Synthesis and Applications.近期固相环六肽合成及应用的相关报告。
Molecules. 2018 Jun 18;23(6):1475. doi: 10.3390/molecules23061475.
3
Chloroalkene dipeptide isosteres as peptidomimetics.氯代烯二肽类同肽作为拟肽。
Methods Enzymol. 2021;656:191-239. doi: 10.1016/bs.mie.2021.04.015. Epub 2021 May 21.
4
A diversity-oriented synthesis strategy enabling the combinatorial-type variation of macrocyclic peptidomimetic scaffolds.一种以多样性为导向的合成策略,可实现大环肽模拟支架的组合式变异。
Org Biomol Chem. 2015 Apr 21;13(15):4570-80. doi: 10.1039/c5ob00371g.
5
Studies on acid stability and solid-phase block synthesis of peptide-peptoid hybrids: ligands for formyl peptide receptors.酸稳定性研究及肽-肽段杂合体的固相阻断合成:甲酰肽受体配体。
Amino Acids. 2019 Feb;51(2):205-218. doi: 10.1007/s00726-018-2656-x. Epub 2018 Sep 28.
6
Pyrrolinone-based peptidomimetics. "Let the enzyme or receptor be the judge".基于吡咯烷酮的肽模拟物。“让酶或受体来评判”。
Acc Chem Res. 2011 Mar 15;44(3):180-93. doi: 10.1021/ar1001186. Epub 2010 Dec 22.
7
One Bead-One Compound (OBOC) Peptidomimetic-Encoded Library Synthesis via Split-and-Pool Methods.通过分割与汇集方法合成的单珠-单化合物(OBOC)肽拟态编码文库。
Methods Mol Biol. 2022;2541:105-120. doi: 10.1007/978-1-0716-2545-3_15.
8
Solid-phase synthesis of pyridones and pyridopyrazines as peptidomimetic scaffolds.
Org Lett. 1999 Nov 4;1(9):1407-9. doi: 10.1021/ol990960u.
9
Solid-Phase Synthesis of Azole-Comprising Peptidomimetics and Coordination of a Designed Analog to Zn.唑类肽拟物的固相合成及设计类似物与 Zn 的配位
Molecules. 2018 Apr 28;23(5):1035. doi: 10.3390/molecules23051035.
10
Comprehensive peptidomimetic libraries targeting protein-protein interactions.针对蛋白质-蛋白质相互作用的综合肽模拟文库。
Acc Chem Res. 2012 Oct 16;45(10):1698-709. doi: 10.1021/ar300025n. Epub 2012 Jul 16.

引用本文的文献

1
Synthesis of Diazacyclic and Triazacyclic Small-Molecule Libraries Using Vicinal Chiral Diamines Generated from Modified Short Peptides and Their Application for Drug Discovery.利用修饰短肽产生的邻位手性二胺合成二氮杂环和三氮杂环小分子文库及其在药物发现中的应用。
Pharmaceuticals (Basel). 2024 Nov 22;17(12):1566. doi: 10.3390/ph17121566.
2
Parallel Synthesis of Piperazine Tethered Thiazole Compounds with Antiplasmodial Activity.具有抗疟活性的哌嗪连接噻唑类化合物的平行合成。
Int J Mol Sci. 2023 Dec 12;24(24):17414. doi: 10.3390/ijms242417414.
3
Polyheterocyclic peptidomimetics: Parallel solid phase synthesis of oligo cyclic guanidines and their inhibition activity against Mycobacterium tuberculosis DNA gyrase.

本文引用的文献

1
Bacteria as genetically programmable producers of bioactive natural products.细菌作为生物活性天然产物的基因可编程生产者。
Nat Rev Chem. 2020 Apr;4(4):172-193. doi: 10.1038/s41570-020-0176-1. Epub 2020 Mar 23.
2
Traceless solid-phase synthesis and β-turn propensity of 1,3-thiazole-based peptidomimetics.基于1,3-噻唑的拟肽的无痕固相合成及β-转角倾向
RSC Adv. 2021 Jan 4;11(2):1050-1056. doi: 10.1039/d0ra10127c. eCollection 2020 Dec 24.
3
The Pictet-Spengler Reaction Updates Its Habits.皮克特-斯宾格勒反应更新其习惯。
多杂环肽模拟物:寡环胍的平行固相合成及其对结核分枝杆菌 DNA 回旋酶的抑制活性。
Bioorg Med Chem Lett. 2023 Sep 1;93:129439. doi: 10.1016/j.bmcl.2023.129439. Epub 2023 Aug 8.
4
Neglected Zoonotic Diseases: Advances in the Development of Cell-Penetrating and Antimicrobial Peptides against Leishmaniosis and Chagas Disease.被忽视的人畜共患疾病:抗利什曼病和恰加斯病的细胞穿透肽与抗菌肽研发进展
Pathogens. 2023 Jul 15;12(7):939. doi: 10.3390/pathogens12070939.
5
Novel Approaches for the Solid-Phase Synthesis of Dihydroquinazoline-2(1)-One Derivatives and Biological Evaluation as Potential Anticancer Agents.新型二氢喹唑啉-2(1H)-酮衍生物的固相合成方法及作为潜在抗癌剂的生物评价。
Molecules. 2022 Dec 5;27(23):8577. doi: 10.3390/molecules27238577.
Molecules. 2020 Jan 19;25(2):414. doi: 10.3390/molecules25020414.
4
In-Peptide Synthesis of Imidazolidin-2-one Scaffolds, Equippable with Proteinogenic or Taggable/Linkable Side Chains, General Promoters of Unusual Secondary Structures.在肽合成中咪唑烷-2-酮支架的应用,可配备蛋白质或标记/连接侧链,具有不寻常二级结构的通用促进剂。
J Org Chem. 2019 May 3;84(9):4992-5004. doi: 10.1021/acs.joc.8b03055. Epub 2019 Apr 22.
5
Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status.肽和拟肽作为潜在的抗肥胖剂:现状概述
Front Nutr. 2019 Feb 18;6:11. doi: 10.3389/fnut.2019.00011. eCollection 2019.
6
Cost-effective production of recombinant peptides in Escherichia coli.大肠杆菌中重组肽的经济有效生产。
N Biotechnol. 2019 Jul 25;51:39-48. doi: 10.1016/j.nbt.2019.02.004. Epub 2019 Feb 18.
7
Making Solid-Phase Peptide Synthesis Greener: A Review of the Literature.固相多肽合成的绿色化:文献综述。
Chem Asian J. 2019 Apr 15;14(8):1088-1097. doi: 10.1002/asia.201801807. Epub 2019 Feb 20.
8
Discovery of potent and selective inhibitors of the Escherichia coli M1-aminopeptidase via multicomponent solid-phase synthesis of tetrazole-peptidomimetics.通过四唑-肽模拟物的多组分固相合成发现对大肠埃希菌 M1-氨基肽酶的有效和选择性抑制剂。
Eur J Med Chem. 2019 Feb 1;163:481-499. doi: 10.1016/j.ejmech.2018.11.074. Epub 2018 Dec 1.
9
Synthesis and β-sheet propensity of constrained N-amino peptides.约束 N-氨基肽的合成及 β-折叠倾向。
Bioorg Med Chem. 2018 Mar 15;26(6):1162-1166. doi: 10.1016/j.bmc.2017.08.017. Epub 2017 Aug 31.
10
Limiting Assumptions in the Design of Peptidomimetics.肽模拟物设计中的限制假设。
Drug Dev Res. 2017 Sep;78(6):245-267. doi: 10.1002/ddr.21406. Epub 2017 Sep 6.